# Optimizing PTCy Dose and Timing

> **NCT03983850** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 105 (actual)

## Conditions studied

- Graft Versus Host Disease
- Hematologic Neoplasms

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT03983850
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-09
- **Primary completion:** 2025-11-25
- **Final completion:** 2026-10-26
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983850, "Optimizing PTCy Dose and Timing". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03983850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*